Calvera presents Phase 2b data for CLV-226 in atopic dermatitis
Investigational antibody met its primary endpoint at week 16, with skin clearance maintained through week 32.
Read more →
Home/News
Regulators accept filing for berolumab-cvra in first-line HER-low breast cancer
Priority review granted, with a decision expected in the second quarter of 2027.
Read more →Late-breaking data for emzaratinib presented at oncology congress
Adjuvant study shows a 41% reduction in risk of recurrence versus placebo.
Read more →Synavo approved for early symptomatic Alzheimer's disease
First approval for trelanemab follows positive Phase 3 results in 1,800 patients.
Read more →Phase 3 study of corvatinib in Crohn's disease completes enrollment
Topline results are expected in the second half of 2026.
Read more →Hemavia approved for hereditary transthyretin amyloidosis
Oral RNA medicine offers once-daily dosing for adults with polyneuropathy.
Read more →Lumacyte approved for HER-low metastatic breast cancer
Antibody–drug conjugate approved after showing improved progression-free survival.
Read more →Calvera begins Phase 3 program for lorvatide in obesity
Program will enroll more than 6,000 adults across 30 countries.
Read more →Glycora approved for type 2 diabetes
Once-weekly injectable peptide improves glycemic control with weight benefits.
Read more →